Xinzhu Wang

Dr. Xinzhu Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
XWXinzhu Wang
Xinzhu Wang
LZLiya Zhao
Liya Zhao
CLChao Liu
Chao Liu
JQJun Qi
Jun Qi
PZPeipei Zhao
Peipei Zhao
XXia Xuekui
Xia Xuekui
Cycloaddition reactions such as intramolecular Diels–Alder (IMDA) are extremely important in constructing multicyclic scaffolds with diverse bioactivities. Using MycB as a biomarker, three new polyketides – Chaetolivacines A (1), B (3), and C (4) – with one known compound Myceliothermophin E (2) comprising of decalin and 4-hydroxy-2-pyridones were obtained from the culture of Chaetomium olivaceum SD-80A under the guidance of gene mining. The structures of these compounds were established using detailed 1D, 2D NMR, and high-resolution electron spray ionization mass spectroscopy (HRESIMS) analysis. The relative and absolute configurations of the compounds 1, 3, and 4 were elucidated by NOESY and ECD. The biosynthesis pathways of these compounds were proposed, which involves in three key genes ChaA [polyketide synthase-non-ribosomal peptide synthetases (PKS-NRPS)], ChaB, and ChaC. Compounds 1–4 were tested for their antimicrobial activities, and compounds 2 and 3 showed moderate bioactivity against Staphylococcus aureus (SA) and methicillin-resistant S. aureus (MRSA) with MIC values of 15.8 and 27.1 μM. The results showed that configuration of C-21 in 3 and 4 is important for anti-SA and anti-MRSA activities. This study reveals the significant potential of the genus Chaetomium in producing new PKS-NRPS, therefore increasing the speed in the mining for new sources of antimicrobial agents.

1 October 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YLYuechao Liu
Yuechao Liu
YXYing Xing
Ying Xing
Hongmei WangHongmei Wang
Hongmei Wang
YSYan Shi
Yan Shi
XWXinzhu Wang
Xinzhu Wang
LCLi Cai
Li Cai
Background LRH1, which promotes the malignant transformation of carcinoma, has recently been documented in several types of malignancies. However, LRH1 has not been assessed as a potential clinical biomarker in any cancer. Methods LRH1 expression was tested in fresh‐frozen tissue samples with quantitative real‐time PCR and Western blot analysis. Surgically resected tumor tissues were collected from 156 non‐small cell lung cancer (NSCLC) patients: 75 with adenocarcinoma and 81 with squamous cell carcinoma. Subsequently, the immunohistochemical expression of LRH1 was examined, and its clinical significance was evaluated. Results LRH1 overexpression was observed in NSCLC carcinoma tissues compared to adjacent normal lung tissues. LRH1 expression was correlated with poorer differentiation (P = 0.023), pathological tumor classification (P < 0.001), advanced pathological tumor node metastasis stage (P = 0.017), adenocarcinoma subtype (P = 0.031), and positive lymph node metastasis (P < 0.001). Multivariate analysis demonstrated that LRH1 expression status was an independent prognostic factor for overall (hazard ratio 1.372, 95% confidence interval 1.225–1.617; P = 0.003) and disease‐free survival (hazard ratio 1.497, 95% confidence interval 1.059–2.115; P = 0.011) in patients who suffered from resectable NSCLC. Conclusion The results of our study indicate that LRH1 predicts NSCLC progression, metastasis, and a dismal prognosis, emphasizing its promising role as a novel target in NSCLC therapies.

16 January 2016 in Chemistry of Natural Compounds
Verified
Journal Article
Closed access
PDF file
RYRuiyun Yang
Ruiyun Yang
XWXinzhu Wang
Xinzhu Wang
BWBo Wei
Bo Wei
DZDe-Xiong Zhou
De-Xiong Zhou
WXWeifeng Xu
Weifeng Xu
JLJun Li
Jun Li

28 November 2020 in Records of Natural Products
Verified
Journal Article
Closed access
XWXinzhu Wang
Xinzhu Wang
PHPeilei Hou
Peilei Hou
YQYanbo Qu
Yanbo Qu
RHRizhen Huang
Rizhen Huang
YFYan Feng
Yan Feng
ZLZhixin Liao
Zhixin Liao
One new phenolic derivative, 1-(4',5'-dihydroxy-2'-methylphenyl)-pentane-1,4-dione (1), along with eighteen known compounds including eight sesquiterpenoids (2–9), one triterpenoid (10), one bisdpoxylignan (11), one coumarin (12), and seven flavonoids (13–19) were isolated from the dried inflorescence of Tibetan herbal medicine Pulicaria insignis. The structure of 1 was established by spectroscopic methods, including HRESIMS, IR, 1D, and 2D NMR. All isolates were assessed for the cytotoxic activities against MGC-803, T24, HepG2, and HeLa cell lines using the MTT assay. The results showed that compound 1 displayed moderate cytotoxicity against Hela and HepG2, and compounds 3, 4, 5, 6, and 13 exhibited potential cytotoxic activities against the four cell lines with IC50 values ranging from 3.05 to 14.37 μM. Notably, compound 5 exhibited significant anti-proliferative activities against HepG2 cell lines with the IC50 values of 3.05 ± 0.36 μM. Further bioactivity investigation showed that compound 5 could block HepG2 cells in the G1 phase of the cell cycle, thereby inhibiting the growth of HepG2 cells and inducing apoptosis in HepG2 cells.

13 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TZTianhui Zhou
Tianhui Zhou
YZYingying Zhang
Yingying Zhang
YLYuqing Lu
Yuqing Lu
ZSZhaodong Sun
Zhaodong Sun
DWDehui Wang
Dehui Wang
YPYang Pan
Yang Pan
Objective: Existing clinical data suggest that Huaier granules effectively improve the condition of PLC patients. However, their specific efficacy and safety in PLC patients remain unclear. This study aimed to investigate the effects of Huaier granules as an adjunctive therapy for PLC patients. Methods: This cohort study includes 4577 PLC patients, with data retrieved up to 2024. The patients were divided into the Huaier group (n = 2404) and a control group (n = 2173), and the treatment effects and safety between the two groups were compared. Review Manager 5.3 was used to analyze the clinical data. The fixed-effects and random-effects models were adopted. Stata 17.0 was used for sensitivity and bias analyses to evaluate publication bias. Results: Heterogeneity testing and analysis using a random-effects model showed that the combination of Huaier granules and conventional treatment significantly reduced the recurrence rate (OR = 0.65, 95% CI 0.50–0.85, p = 0.002) and improved the one-year survival rate (OR = 0.79, 95% CI 0.65–0.96, p = 0.02). Huaier granules also improved quality of life, reduced AFP levels (p < 0.00001), and significantly impacted immune function by altering the levels of the T lymphocyte subtypes CD3+, CD4+, CD8+ and the CD4+/CD8+ ratio. When Huaier granules were used in combination with other medications, no significant changes in side effects were observed. Conclusions: Huaier combination therapy shows good therapeutic efficacy and safety in PLC patients. However, this conclusion needs to be further validated through prospective clinical studies.

6 November 2022 in Natural Product Research
Verified
Journal Article
Closed access
XWXinzhu Wang
Xinzhu Wang
QMQingzhou Meng
Qingzhou Meng
HCHaiyan Chen
Haiyan Chen
XYXin Yin
Xin Yin
HDHuan-Qin Dai
Huan-Qin Dai
LZLixin Zhang
Lixin Zhang
A pair of new quinolone alkaloid enantiomers, (Ra)-(-)-viridicatol (1) and (Sa)-(+)-viridicatol (4), and seven known compounds, namely, 2, 3 and 5–9, were isolated from Penicillium christenseniae SD.84. The structures of 1 and 4 were determined using NMR and HRESIMS data. Theoretical calculations through CD and ECD confirmed 1 and 4 as a pair of enantiomers. The MIC values of 4 against Staphylococcus aureus and methicillin-resistant S. aureus were 12.4 and 24.7 μM, respectively, compound 1 had no inhibitory activity. Antimicrobial assays of 2, 3, and 5–7 showed a moderate activity against S. aureus and methicillin-resistant S. aureus. This study demonstrated the remarkable potential of Penicillium sp. to produce new drug-resistant leading compounds, thereby advancing the mining for new sources of antimicrobial agents. Graphical Abstract